-
Our Vision is to improve healthcare as a global provider of innovative and reliable diagnostic tests. -
Our Mission is to identify and develop novel patentable diagnostic markers and technologies which can be commercialised to meet clinical needs, both in the laboratory and at the point of care. -
We will collaborate with partners, create branded products and identify complementary businesses which support our objective of continuing to grow as a respected and profitable healthcare company. -
Our Values include meeting all current and future regulatory, quality and environmental standards appropriate for our industry and the countries in which we operate.
Interim Results Announcement of the Results for the half year ended 30 June 2011
Axis-Shield plc announced its interim results at 07:00 BST/08:00 CEST on Wednesday 24 August 2011.
A copy of the results presentation is below, along with other recent presentations:
| Related Documents | |
 |
Interims Presentation 2011 (PDF 1.3 Mb) |
 |
Final AGM 2011 Presentation (PDF 2.3 Mb) |
|
|
2010 Preliminary Results Presentation - Final (PDF 1.3 Mb) |
|
|
2011 J.P. Morgan Presentation (PDF 2.81Mb) |
|
|
Axis-Shield Jefferies Conference October 2010 (PDF 1Mb) |
|
|
Axis-Shield UBS Conference September 2010 (PDF 1Mb) |
|
|
Oslo Luncheon Presentation (PDF 1Mb) |
|
|
2010 Interim Results Presentation (PDF 1.4Mb) |
* NB: These pdfs will open in the same browser window.
Axis-Shield at a Glance
A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories and at the point of care.
Focus on Afinion
Axis-Shield's award winning point-of-care test system is designed for maximum simplicity coupled with laboratory accuracy and reliability for a number of key markers important for improved patient management.
